Antiplatelet use after intracerebral hemorrhage

Neurology. 2006 Jan 24;66(2):206-9. doi: 10.1212/01.wnl.0000194267.09060.77.


Background: Survivors of intracerebral hemorrhage are at risk for recurrent intracerebral hemorrhage and ischemic cardiovascular and cerebrovascular disease.

Objective: To determine whether antiplatelet therapy increases the risk of recurrent intracerebral hemorrhage.

Methods: The authors reviewed data from consecutive survivors of primary intracerebral hemorrhage enrolled in a single-center prospective cohort study. Survivors were followed by telephone interview; recurrent intracerebral hemorrhage and post-index antiplatelet agent use and duration were recorded. Cox proportional hazards models was used with antiplatelet agent exposure as a time-dependent variable to assess the effect of antiplatelet agent use on recurrent intracerebral hemorrhage, stratified by lobar and deep hemispheric location.

Results: Recurrent intracerebral hemorrhage was more common in survivors of lobar hemorrhage compared with survivors of deep hemorrhage (cumulative 2-year rate 22% vs 4%; p = 0.007). Antiplatelet agents were prescribed in 22% of intracerebral hemorrhage survivors (27/127 lobar, 19/80 deep hemispheric), most commonly for prevention of ischemic heart disease. Antiplatelet agent use was not associated with intracerebral hemorrhage recurrence in survivors of either lobar hemorrhage (hazard ratio [HR] 0.8, 95% CI 0.3 to 2.3, p = 0.73) or of deep hemorrhage (HR 1.2, 95% CI 0.1 to 14.3, p = 0.88).

Conclusion: Antiplatelet agent use is relatively common following intracerebral hemorrhage but did not appear to be associated with a large increased risk of intracerebral hemorrhage recurrence in this observational study.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cerebral Hemorrhage / chemically induced*
  • Cerebral Hemorrhage / classification
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Medical Records
  • Middle Aged
  • Myocardial Ischemia / prevention & control
  • Platelet Aggregation Inhibitors / adverse effects*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Proportional Hazards Models
  • Prospective Studies
  • Recurrence
  • Risk Assessment
  • Survivors


  • Platelet Aggregation Inhibitors